Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a special light boost brainpower in depression?

NCT ID NCT07508215

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 5 times

Summary

This study tests whether a specially designed bright light can improve cognitive problems like memory and attention in people with major depressive disorder. 120 adults with depression and cognitive issues will receive either the bright light or a dim red placebo light for four weeks. Researchers will also use brain scans to see how the light affects brain circuits linked to thinking.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bright light therapy (spectrally optimized light)
What this could lead to
If it works, this could offer a simple, drug-free way to help with the thinking and memory problems that often come with depression.
What could go wrong
This is an early study with only 120 people, and the light might not work better than a placebo. The results may not apply to everyone with depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

The inclusion and exclusion criteria for MDD patients. 1、Inclusion Criteria: 1. MDD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-Ⅳ), first episode or recurrence, confirmed by an experienced psychiatrist using the Mini International Neuropsychiatric Interview. 2. Age between 18 and 60 years; and gender no-limited; 3. The severity of MDD symptoms must be ≥14 scores on the HAMD-17; 4. With CI currently, defined as a total score of \<70 on the SC; 5. A SSRI monotherapy at stable dosages for at least 4 weeks; or medication-free status; 6. Education level above primary school, able to understand and cooperate in completing the study procedures; 7. Voluntarily participating in this study and sign the informed consent before enrollment. 2、Exclusion Criteria: 1. Current or past diagnosis of any disorder other than MDD according to DSM-Ⅳ criteria; 2. The scores on the Young Mania Rating Scale (YMRS) are\>8; 3. The participants who have undergone other intervention in addition to SSRIs whinin the past 6 months or now, or who plan to do that in 1 month; 4. The participants with strong self-blame, self-harm, or suicidal risks (the HAMD-17 suicide item score of ≥3); 5. The participants with severe physical illnesses, including heart failure, renal failure, severe liver dysfunction, hyperthyroidism, or hypothyroidism; Or a history of severe brain trauma or organic brain pathology (e.g., intracerebral hemorrhage, large-area cerebral infarction, encephalitis, epilepsy), as well as neurological diseases; 6. The participants with any degree of retinal pathology, including retinal dystrophy, age-related macular degeneration, diabetic retinopathy, cataracts, glaucoma, or other ocular diseases; 7. The participants with photosensitive conditions, such as systemic lupus erythematosus, porphyria, chronic photodermatitis, solar urticaria, or those currently receiving medications that may increase photosensitivity (e.g., phenothiazines, antimalarials, propranolol, hypericin, stimulants, or chronic treatment with nonsteroidal anti-inflammatory drugs); 8. Pregnant or lactating women; 9. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia; 10. The participants deem unsuitable for inclusion in this study by the investigator for other reasons. Withdrawal and Termination Criteria: 1. The participants meet one of the exclusion criteria above after enrollment; 2. When the participants' treatment regimen need change; 3. The participants who fail to cooperate or voluntarily withdraw from the study; 4. Due to severe adverse events, the patients are unable to tolerate phototherapy; 5. The participants who fail to adhere to the study protocol intervention for three consecutive days or for a cumulative duration exceeding seven days; 6. Cancellation of the study. The inclusion and exclusion criteria for Health controls 1\. Inclusion criteria 1. Age between 18 and 60 years; and gender no-limited; 2. Without CI currently, defined as a total score of ≤ 70 on the SC; 3. Education level above primary school, able to understand and cooperate in completing the study procedures; 4. Voluntarily participating in this study and sign the informed consent before enrollment. 2.Exclusion criteria 1. Current or past diagnosis of any psychiatric disorders, or history of substance/drug abuse or dependence; 2. Current or past diagnosis of severe somatic diseases, such as heart failure, renal failure, severe liver dysfunction, or hyperthyroidism/hypothyroidism; 3. History of severe traumatic brain injury or organic brain lesions; 4. Pregnant or lactating women; 5. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia. 6. The participants deem unsuitable for inclusion in this study by the investigator for other reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bright light treatment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University Sixth Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100191, China

  • Yan'an Third People's Hospital

    RECRUITING

    Yanan, Shanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.